<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1986">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855630</url>
  </required_header>
  <id_info>
    <org_study_id>20-01023</org_study_id>
    <nct_id>NCT04855630</nct_id>
  </id_info>
  <brief_title>Combating Alzheimer's Through Sleep and Exercise</brief_title>
  <acronym>CASE</acronym>
  <official_title>Combating Alzheimer's Through Sleep and Exercise (CASE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's/dementia is an increasingly critical public health risk, with over 50 million&#xD;
      Americans at risk for the disease. To stem the burden of Alzheimer's disease, prophylactic&#xD;
      and protective strategies such as physical activity and sleep have been recommended to reduce&#xD;
      the risk of cognitive decline and Alzheimer's/dementia. Previous research indicate that&#xD;
      exercise improves cognition and lowers dementia risk and may be a promising intervention to&#xD;
      address dementia risk in the general population. Sleep, specifically slow wave sleep, may&#xD;
      reduce dementia risk, based on previous work showing that greater levels of slow wave sleep&#xD;
      was related to higher cognition. However, little is known about the independent and combined&#xD;
      effects exercise and sleep have on cognition. The proposed study therefore aims to&#xD;
      investigate the independent and combined effects exercise (aerobic and stretching) and sleep&#xD;
      have on cognition and what heart health, sleep and stress correlates confound this&#xD;
      association.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cholesterol Level</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol Level</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-Density Lipoprotein (HDL) Level</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-Density Lipoprotein (HDL) Level</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculated Low-Density Lipoprotein (LDL) Level</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculated Low-Density Lipoprotein (LDL) Level</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Level</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Level</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high-sensitivity C-reactive protein (hs-CRP) Level</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high-sensitivity C-reactive protein (hs-CRP) Level</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from blood sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from Fitbit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from Fitbit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from Fitbit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from Fitbit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Sleep Duration</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from DREEM 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Sleep Duration</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from DREEM 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow Wave Sleep Duration</measure>
    <time_frame>Week 6</time_frame>
    <description>Measured from DREEM 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow Wave Sleep Duration</measure>
    <time_frame>Week 12</time_frame>
    <description>Measured from DREEM 2</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Sleep Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise + Sleep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DREEM 2 Headband</intervention_name>
    <description>Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic CBT-I intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).</description>
    <arm_group_label>Exercise + Sleep</arm_group_label>
    <arm_group_label>Sleep Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fitbit</intervention_name>
    <description>Participants will partake in a guided exercise routine (30-minute mild circuit training session while VO2 is estimated from a Fitbit device twice per week for 3 months).</description>
    <arm_group_label>Exercise + Sleep</arm_group_label>
    <arm_group_label>Exercise Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 45 years and older&#xD;
&#xD;
          2. Able to perform mild exercise&#xD;
&#xD;
          3. Able to wear DREEM 2 Headband&#xD;
&#xD;
          4. Able to wear a Fitbit wrist watch&#xD;
&#xD;
          5. Able to perform the Everlywell biomarker procedure&#xD;
&#xD;
          6. Able to Understand and Speak English&#xD;
&#xD;
          7. Able to operate a digital device like mobile phone, iPad, or computer&#xD;
&#xD;
          8. Self-reported history of problems with cognitive impairment: memory, concentration,&#xD;
             and processing information&#xD;
&#xD;
          9. Only participants cognitively able and willing to provide consent will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under 45 years old&#xD;
&#xD;
          2. Prohibited from or unable to perform mild exercise&#xD;
&#xD;
          3. Unable to wear wrist watch or headband devices, or unable to supply pinprick blood&#xD;
             sample for any reason&#xD;
&#xD;
          4. Unable to speak or understand English&#xD;
&#xD;
          5. Unable to use mobile device/smartphone technology&#xD;
&#xD;
          6. Unable or unwilling to consent for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azizi A Seixas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Azizi A Seixas, PhD</last_name>
    <phone>646-501-3430</phone>
    <email>Azizi.seixas@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesse Moore, MS</last_name>
    <phone>908-884-1721</phone>
    <email>Jesse.moore@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesse Moore, MS</last_name>
      <email>Jesse.moore@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Azizi A Seixas, PhD</last_name>
      <email>Azizi.seixas@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Azizi A Seixas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arlener Turner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Williams, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debbie Chung, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>January 5, 2022</last_update_submitted>
  <last_update_submitted_qc>January 5, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Azizi Seixas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Azizi.seixas@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

